Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Debt Securities, Available-for-sale, Amortized Cost, Noncurrent

Debt Securities, Available-for-sale, Amortized Cost, Noncurrent at other companies

Wells Fargo & Company logo
Wells Fargo & CompanyWFC
$156.64B+6.0%
Wintrust Financial logo
Wintrust FinancialWTFC
$52.66M-14.6%
Stifel Financial logo
Stifel FinancialSF
$25.99M-74.8%
Paychex logo
PaychexPAYX
$0-100%
BK
BKBK
$107.65B+9.8%
Popular logo
PopularBPOP
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's debt securities, available-for-sale, amortized cost, noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's debt securities, available-for-sale, amortized cost, noncurrent?
Ionis Pharmaceuticals (IONS) reported debt securities, available-for-sale, amortized cost, noncurrent of $632.47M in Q1 2026.
How has Ionis Pharmaceuticals's debt securities, available-for-sale, amortized cost, noncurrent changed year-over-year?
Ionis Pharmaceuticals's debt securities, available-for-sale, amortized cost, noncurrent decreased by 7.1% year-over-year, from $680.88M to $632.47M.
What is the long-term trend for Ionis Pharmaceuticals's debt securities, available-for-sale, amortized cost, noncurrent?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's debt securities, available-for-sale, amortized cost, noncurrent has grown at a 4.8% compound annual growth rate (CAGR), from $638.62M to $771.63M.
What does debt securities, available-for-sale, amortized cost, noncurrent mean?
The book value of non-current debt securities before adjusting for market price changes.
How do you interpret debt securities, available-for-sale, amortized cost, noncurrent?
An increase indicates a longer-term investment horizon for the company's excess cash reserves.
How does debt securities, available-for-sale, amortized cost, noncurrent compare across companies?
Standard reporting for long-term treasury assets in the life sciences sector.